If side effects are too much, you might try a lower dose, smaller meals, avoiding fatty foods, or another GLP-1
doi: 10.1002/fsn3.4046 18
Second-generation TKIs Dasatinib, nilotinib, ponatinib, and bosutinib are second-generation TKIs that are used for treatment of Ph+CML
The lifetime risk of patients with NF-1 developing MPNSTs has been estimated at 813%, with a yearly risk of developing MPNSTs of 0.16% compared to 0.001% in the general population
Whereas patients taking antibiotics typically see a quick, demonstrable effect, GLP-1 treatment may be drawn out over weeks and months and potentially years, Zollo told Healthcare Brew